Myomo, Inc. (MYO)
USD 4.05
(-6.9%)
USD 4.05
(-6.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -6.27 Million USD | -30.84% |
| 2022 | -4.79 Million USD | 67.6% |
| 2021 | -14.78 Million USD | -22.55% |
| 2020 | -12.06 Million USD | -565.77% |
| 2019 | -1.81 Million USD | 72.29% |
| 2018 | -6.54 Million USD | 49.53% |
| 2017 | -12.95 Million USD | -378.25% |
| 2016 | 4.65 Million USD | 362.74% |
| 2015 | 1 Million USD | 197.32% |
| 2014 | -1.03 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.94 Million USD | 21.07% |
| 2024 Q2 | -5.48 Million USD | -10.78% |
| 2023 FY | -6.27 Million USD | -30.84% |
| 2023 Q4 | -6.27 Million USD | -1.09% |
| 2023 Q3 | -6.2 Million USD | -9.11% |
| 2023 Q2 | -5.68 Million USD | 35.54% |
| 2023 Q1 | -8.81 Million USD | -84.03% |
| 2022 Q3 | -6.75 Million USD | 28.64% |
| 2022 Q4 | -4.79 Million USD | 29.09% |
| 2022 FY | -4.79 Million USD | 67.6% |
| 2022 Q1 | -12.07 Million USD | 18.33% |
| 2022 Q2 | -9.47 Million USD | 21.59% |
| 2021 Q3 | -11.83 Million USD | 8.22% |
| 2021 Q2 | -12.88 Million USD | 21.99% |
| 2021 FY | -14.78 Million USD | -22.55% |
| 2021 Q1 | -16.52 Million USD | -36.91% |
| 2021 Q4 | -14.78 Million USD | -25.01% |
| 2020 Q3 | -13.23 Million USD | -37.07% |
| 2020 FY | -12.06 Million USD | -565.77% |
| 2020 Q4 | -12.06 Million USD | 8.85% |
| 2020 Q2 | -9.65 Million USD | 21.47% |
| 2020 Q1 | -12.29 Million USD | -578.53% |
| 2019 Q2 | -6.66 Million USD | 27.78% |
| 2019 Q3 | -4.32 Million USD | 35.1% |
| 2019 FY | -1.81 Million USD | 72.29% |
| 2019 Q4 | -1.81 Million USD | 58.12% |
| 2019 Q1 | -9.23 Million USD | -41.17% |
| 2018 Q4 | -6.54 Million USD | 28.07% |
| 2018 Q1 | -14.11 Million USD | -8.93% |
| 2018 FY | -6.54 Million USD | 49.53% |
| 2018 Q2 | -11.68 Million USD | 17.23% |
| 2018 Q3 | -9.09 Million USD | 22.17% |
| 2017 Q3 | -3.06 Million USD | 39.62% |
| 2017 Q2 | -5.07 Million USD | -187.1% |
| 2017 FY | -12.95 Million USD | -378.25% |
| 2017 Q1 | 5.82 Million USD | 25.02% |
| 2017 Q4 | -12.95 Million USD | -323.13% |
| 2016 Q2 | 2.6 Million USD | 149.97% |
| 2016 FY | 4.65 Million USD | 362.74% |
| 2016 Q1 | 1.04 Million USD | 3.59% |
| 2016 Q4 | 4.65 Million USD | 0.0% |
| 2015 FY | 1 Million USD | 197.32% |
| 2015 Q4 | 1 Million USD | 0.0% |
| 2015 Q3 | 1 Million USD | 0.0% |
| 2015 Q1 | 2.42 Million USD | 0.0% |
| 2014 FY | -1.03 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott Laboratories | 8.97 Billion USD | 100.07% |
| Allurion Technologies Inc. | 3.82 Million USD | 264.136% |
| Artivion, Inc. | 300.4 Million USD | 102.087% |
| Avanos Medical, Inc. | 121.4 Million USD | 105.165% |
| Butterfly Network, Inc. | -109.6 Million USD | 94.28% |
| Butterfly Network, Inc. | -109.6 Million USD | 94.28% |
| Bio-Rad Laboratories, Inc. | 1 Billion USD | 100.626% |
| Boston Scientific Corporation | 8.62 Billion USD | 100.073% |
| CONMED Corporation | 966.95 Million USD | 100.648% |
| Edwards Lifesciences Corporation | -449.1 Million USD | 98.604% |
| Paragon 28, Inc. | 36.39 Million USD | 117.23% |
| Glaukos Corporation | 290.27 Million USD | 102.16% |
| Globus Medical, Inc. | 53.11 Million USD | 111.805% |
| Inspire Medical Systems, Inc. | -160.69 Million USD | 96.098% |
| Integer Holdings Corporation | 1.01 Billion USD | 100.616% |
| Medtronic plc | 24.76 Billion USD | 100.025% |
| Nevro Corp. | 117.61 Million USD | 105.331% |
| Owlet, Inc. | -1.34 Million USD | -367.562% |
| Penumbra, Inc. | 66.85 Million USD | 109.378% |
| Vicarious Surgical Inc. | -37.99 Million USD | 83.496% |
| Smith & Nephew plc | 2.78 Billion USD | 100.225% |
| Sonendo, Inc. | 26.34 Million USD | 123.802% |
| STERIS plc | 3.17 Billion USD | 100.197% |
| Stryker Corporation | 10.02 Billion USD | 100.063% |
| Vapotherm, Inc. | 102.66 Million USD | 106.107% |
| Zimmer Biomet Holdings, Inc. | 5.57 Billion USD | 100.112% |